Chris P. Pescott

Chris P. Pescott

Auto-generated profile, based on publicly available information

Chris P. Pescott

Merck KGaA, Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
ABAsh Bullement
Ash Bullement
PNPaul Nathan
Paul Nathan
AWAnna Willis
Anna Willis
AAAmerah Amin
Amerah Amin
CLCameron Lilley
Cameron Lilley
MBMurtuza F Bharmal
Murtuza F Bharmal
Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a newly available treatment option for mMCC, versus standard care (SC), from a UK National Health Service perspective.

21 January 2015 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
NLNaomi van der Linden
Naomi van der Linden
JBJan Buter
Jan Buter
CPChris P. Pescott
Chris P. Pescott
RLRoy Lalisang
Roy Lalisang
JBJan Paul de Boer
Jan Paul de Boer
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot
For patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), chemotherapy can prolong life and alleviate symptoms. However, expected gains may be small, not necessarily outweighing considerable toxicity and high costs. Treatment choice is to a large extent dependent on preferences of doctors and patients and data on these choices are scarce. The purpose of this study is to obtain real-world information on palliative systemic treatment and costs of R/M SCCHN in the Netherlands. In six Dutch head and neck treatment centers, data were collected on patient and tumor characteristics, treatment patterns, disease progression, survival, adverse events, and resource use for R/M SCCHN, between 2006 and 2013. 125 (14 %) out of 893 R/M SCCHN patients received palliative, non-trial first-line systemic treatment, mainly platinum + 5FU + cetuximab (32 %), other platinum-based combination therapy (13 %), methotrexate monotherapy (27 %) and capecitabine monotherapy (14 %). Median progression-free survival and overall survival were 3.4 and 6.0 months, respectively. 34 (27 %) patients experienced severe adverse events. Mean total hospital costs ranged from €10,075 (±€9,891) (methotrexate monotherapy) to €39,459 (±€21,149) (platinum + 5FU + cetuximab). Primary cost drivers were hospital stays and anticancer drug treatments. Major health care utilization and costs are involved in systemically treating R/M SCCHN patients with a limited survival.

17 January 2020 in Journal of Medical Economics
Verified
Journal Article
Open access
SSSebastian Stintzing
Sebastian Stintzing
IOIlse van Oostrum
Ilse van Oostrum
CPChris P. Pescott
Chris P. Pescott
PRPhilippe Ronga
Philippe Ronga
BHBart Heeg
Bart Heeg
VHVolker Heinemann
Volker Heinemann
Aims: This analysis evaluates the cost-effectiveness of first-line treatment with FOLFIRI + cetuximab vs FOLFIRI + bevacizumab (FOLFIRI-cet vs FOLFIRI-bev) for patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany based on the randomized phase 3 FIRE-3 trial. For patients with RAS wt mCRC, FOLFIRI-cet yielded statistically significant median overall survival gains over FOLFIRI-bev. Materials and methods: A standard 3-state partitioned survival cost-utility model was developed to compare the health benefits and costs of treatment from a German social health insurance perspective using individual patient–level trial data. Health outcomes were reported in life-years (LYs) and quality-adjusted life-years (QALYs) gained. Survival was estimated based on Kaplan-Meier (KM) curves supplemented with best-fitting parametric survival model extrapolations. Subgroup analyses of patients with a left-sided primary tumor location or patients with metastases confined to the liver were performed. Results: In the modified intention-to-treat analysis, FOLFIRI-cet, providing 0.68 additional LYs (0.53 QALYs), yielded incremental cost-effectiveness ratios (ICERs) of €36,360/LY and €47,250/QALY. In subgroup analyses, patients experienced improved survival gains without a corresponding increase in costs, resulting in lower ICERs. Our model was most sensitive to changes in treatment duration across all lines of therapy, utility of progressive disease, as well as patients’ weight and body surface area. Limitations: This cost-effectiveness analysis was based on patient-level data from the FIRE-3 trial. Trial outcomes may not adequately reflect those in the real-world setting. Additionally, resource use and costs were obtained from tariff lists, which do not account for differences in treatment practice. These considerations limit generalizability of outcomes to other countries, or within the German healthcare setting. Conclusions: Based on our analyses, FOLFIRI-cet is cost-effective compared with FOLFIRI-bev in patients with RAS wt mCRC, with ICERs well below willingness-to-pay thresholds for diseases with a high burden.

17 July 2018 in Health Economics Review
Verified
Journal Article
Open access
PDF file
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot
ERElisabeth M. van Rooijen
Elisabeth M. van Rooijen
CPCornelis J. A. Punt
Cornelis J. A. Punt
CPChris P. Pescott
Chris P. Pescott
To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC in eight hospitals in the Netherlands between 2009 and 2012 were included in our real-world study. Outcome measures were costs per life-year (LY) and costs per quality-adjusted LY (QALY) gained. A Markov model was developed, and a time horizon of four years was applied. Outcomes were calculated from Kaplan-Meier survival curves from patient-level data and literature. Direct medical costs were estimated in all centers (2013 values), and incremental cost-effectiveness ratios (ICERs) were calculated. Results were discounted, and a probabilistic sensitivity analysis was performed. Administration of cetuximab in third-line treatment of mCRC resulted in a gain of 0.29 LYs and 0.25 QALYs compared with BSC. In the four-year study period, average discounted healthcare costs were €36,637 in the cetuximab group vs. €3648 in the BSC group. The discounted ICERs of cetuximab vs. BSC in the real-world setting were €114,907and €133,527 per LY and QALY gained, respectively. Results of this cost-effectiveness analysis showed that third-line treatment with cetuximab for patients with KRAS (exon 2) wt mCRC offered clinical benefits at additional cost. The real-world ICERs were in line with those of previously published cetuximab and panitumumab cost-utility models.

1 April 2021 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
CPChris P Pescott
Chris P Pescott
EBEmmanuelle Boutmy
Emmanuelle Boutmy
MBMichael Batech
Michael Batech
PRPhilippe Ronga
Philippe Ronga
FLFrancois-Xavier Lamy
Francois-Xavier Lamy
Aim: To compare healthcare resource utilization (HRU) and healthcare costs (HC) for every-2-week (Q2W) versus weekly (Q1W) cetuximab in metastatic colorectal cancer (mCRC). Patients & methods: Pati...

1 November 2020 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Closed access
FLFrancois-Xavier Lamy
Francois-Xavier Lamy
MBMichael Batech
Michael Batech
EBEmmanuelle Boutmy
Emmanuelle Boutmy
PRPhilippe Ronga
Philippe Ronga
SSShaista Salim
Shaista Salim
CPChris P Pescott
Chris P Pescott
Aim: To test the noninferiority of cetuximab administered every 2 weeks (Q2W) versus once weekly (Q1W) in treating metastatic colorectal cancer (mCRC) with regard to overall survival (OS). Patients: Patients receiving cetuximab plus chemotherapy for mCRC in a line-agnostic setting. Methods: This cohort study in IBM MarketScan followed patients from initiation of cetuximab for mCRC until the end of the data availability period, proxy-based death or loss of insurance coverage for >30 days. Results : The hazard ratio for OS was 0.94 (0.85–1.03), and the inferiority hypothesis was rejected at p < 0.001. No significant differences were noted in rates of safety events between Q2W and Q1W. Conclusion: Our real-world study confirmed the noninferiority of cetuximab administered Q2W versus Q1W for OS.